Get the Stockscreener App
5.32
0.60%
-0.012
Coya Therapeutics Inc stock is traded at $5.32, with a volume of 43,709.
It is down -0.60% in the last 24 hours and down -19.58% over the past month.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
See More
Previous Close:
$5.332
Open:
$5.35
24h Volume:
43,709
Relative Volume:
0.57
Market Cap:
$88.50M
Revenue:
-
Net Income/Loss:
$-14.88M
P/E Ratio:
-5.4286
EPS:
-0.98
Net Cash Flow:
$-10.29M
1W Performance:
-10.17%
1M Performance:
-19.58%
6M Performance:
-18.71%
1Y Performance:
-29.80%
1-Day Range:
$5.275
$5.4982
1-Week Range:
$5.305
$5.9874
52-Week Range:
$4.65
$10.24
Coya Therapeutics Inc Stock (COYA) Company Profile
Name
Coya Therapeutics Inc
Sector
Industry
Phone
650.739.3939
Address
12645 MEMORIAL DR., SUITE F1 #305, HOUSTON
Compare COYA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COYA
Coya Therapeutics Inc
|
5.29 | 95.50M | 0 | -14.88M | -10.29M | -0.98 |
|
ONC
Beone Medicines Ltd Adr
|
245.79 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.73 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.61 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.59 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Coya Therapeutics Inc Stock (COYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-04-24 | Initiated | D. Boral Capital | Buy |
Coya Therapeutics Inc Stock (COYA) Latest News
(COYA) Investment Report - news.stocktradersdaily.com
Brokers Issue Forecasts for COYA Q1 Earnings - Defense World
Q3 EPS Forecast for Coya Therapeutics Increased by Analyst - Defense World
Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update - Business Wire
Coya Therapeutics: Promising Developments and Strategic Partnerships Drive Buy Rating - TipRanks
Coya Therapeutics First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
FY2026 Earnings Forecast for COYA Issued By Chardan Capital - Defense World
Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference - Business Wire
Coya Therapeutics, Inc. (NASDAQ:COYA) Stock Holdings Lifted by Tower Research Capital LLC TRC - Defense World
Coya Therapeutics (COYA): Analyst Maintains Buy Rating and Price - GuruFocus
Critical Survey: Coya Therapeutics (NASDAQ:COYA) vs. BioVie (NASDAQ:BIVI) - Defense World
Coya Therapeutics Reports Q1 2025 Financial Results - TipRanks
Coya (COYA) Reports Lower Q1 Revenue Than Expected | COYA Stock News - GuruFocus
Coya Therapeutics (COYA) Reports Q1 EPS and Cash Position - GuruFocus
Coya Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Coya Therapeutics to Participate in Two Upcoming Conferences in May 2025 - Stock Titan
Coya Therapeutics (COYA) Projected to Post Quarterly Earnings on Thursday - Defense World
How To Trade (COYA) - news.stocktradersdaily.com
Coya Therapeutics, Inc. (NASDAQ:COYA) Shares Acquired by Geode Capital Management LLC - Defense World
Coya Therapeutics advances COYA 303 for inflammatory diseases - MSN
Is Coya Therapeutics, Inc. (COYA) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Coya Therapeutics’ (COYA) “Buy” Rating Reaffirmed at Chardan Capital - Defense World
Biotech Company Reports Promising Neurological Treatment in Clinical Study - streetwisereports.com
Coya Therapeutics: Treg Proof-Of-Concept Continues With Interim FTD Data Release - Seeking Alpha
Coya Therapeutics Announce Positive Interim Result from - openPR.com
Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia – EventsNewsAsia.com - eventsnewsasia.com
Biotech Discovers Revolutionary Immunotherapy in Houston - streetwisereports.com
Coya stock in focus after interim results for dementia drug - Seeking Alpha
Coya Reports Positive Data From Proof Of Concept Open-label Study Of IL-2 And CTLA4-Ig Combo In FTD - Nasdaq
Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia - businessnews.ph
Coya Therapeutics Announces Positive Interim Results Of An Investigator-Initiated Open Label Study With Low-Dose IL-2 And CTLA4-Ig Combination Treatment In Five Patients With Mild To Moderate Frontotemporal Dementia - marketscreener.com
Revolutionary Frontotemporal Dementia Treatment Prevents Cognitive Decline in All Trial Patients - Stock Titan
Coya Therapeutics (NASDAQ:COYA) Earns Buy Rating from D. Boral Capital - Defense World
Wall Street Analysts See a 144.73% Upside in Coya Therapeutics, Inc. (COYA): Can the Stock Really Move This High? - Yahoo Finance
AI in Clinical Trials Market Growth 2025: Trends, Consumer - openPR.com
Coya Therapeutics (NASDAQ:COYA) Trading 8.6% Higher – What’s Next? - Defense World
Coya Therapeutics, Inc. Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death) - marketscreener.com
Breakthrough: New GLP-1/IL-2 Combo Drug Outperforms Standard Therapy by 42% in Alzheimer's Research - Stock Titan
(COYA) Long Term Investment Analysis - news.stocktradersdaily.com
Is Coya Therapeutics (COYA) the Top Healthcare Stock to Buy According to Billionaire David Einhorn? - Yahoo
Coya Therapeutics stock hits 52-week low at $4.72 - Investing.com Australia
Coya Therapeutics stock hits 52-week low at $4.72 By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Exosomes Pipeline 2025: MOA and ROA Insights, Clinical Trials - openPR.com
Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025 - The Joplin Globe
GMP Production of Exosomes Slated for Later This Year - streetwisereports.com
Coya Therapeutics Inc Stock (COYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Coya Therapeutics Inc Stock (COYA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Swaminathan Arun | Chief Executive Officer |
Nov 13 '24 |
Buy |
7.36 |
5,000 |
36,797 |
10,000 |
| Grossman Fred | Chief Medical Officer |
Nov 11 '24 |
Buy |
7.37 |
2,710 |
19,973 |
2,710 |
| Swaminathan Arun | Chief Executive Officer |
Nov 11 '24 |
Buy |
7.34 |
5,000 |
36,689 |
5,000 |
2.38%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):